Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Open access

Abstract

Background Microsatellite-stable metastatic colorectal cancer is typically unresponsive to immunotherapy. This phase 3 study was designed to assess atezolizumab plus cobimetinib in metastatic colorectal cancer. Here, we report the comparison of atezolizumab plus cobimetinib or atezolizumab monotherapy versus regorafenib in the third-line setting.Methods IMblaze 370 is a multicentre, open-label, phase 3, randomised, controlled trial, done at 73 academic medical centres and community oncology practices in 11 countries. Patients aged at least 18 years with unresectable locally advanced or metastatic colorectal cancer, baseline Eastern Cooperative Oncology Group performance status of 0-1, and disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled. We used permuted-block randomisation (block size four) to assign patients (2:1:1) via an interactive voice and web response system to atezolizumab (840 mg intravenously every 2 weeks) plus cobimetinib (60 mg orally once daily for days 1-21 of a 28-day cycle), atezolizumab monotherapy (1200 mg intravenously every 3 weeks), or regorafenib (160 mg orally once daily for days 1-21 of a 28-day cycle). Stratification factors were extended RAS status (wild-type vs mutant) and time since diagnosis of first metastasis (<18 months vs ≥18 months). Recruitment of patients with high microsatellite instability was capped at 5%. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the population of patients who received at least one dose of their assigned treatment. IMblaze370 is ongoing and is registered with ClinicalTrials.gov, number NCT02788279.Findings Between July 27, 2016, and Jan 19, 2017, 363 patients were enrolled (183 patients in the atezolizumab plus cobimetinib group, 90 in the atezolizumab group, and 90 in the regorafenib group). At data cutoff (March 9, 2018), median follow-up was 7·3 months (IQR 3·7-13·6). Median overall survival was 8·87 months (95% CI 7·00-10·61) with atezolizumab plus cobimetinib, 7·10 months (6·05-10·05) with atezolizumab, and 8·51 months (6·41-10·71) with regorafenib; the hazard ratio was 1·00 (95% CI 0·73-1·38; p=0·99) for the combination versus regorafenib and 1·19 (0·83-1·71; p=0·34) for atezolizumab versus regorafenib. Grade 3-4 adverse events were reported in 109 (61%) of 179 patients in the atezolizumab plus cobimetinib group, 28 (31%) of 90 in the atezolizumab group, and 46 (58%) of 80 in the regorafenib group. The most common all-cause grade 3-4 adverse events in the combination group were diarrhoea (20 [11%] of 179), anaemia (ten [6%]), increased blood creatine phosphokinase (12 [7%]), and fatigue (eight [4%]). Serious adverse events were reported in 71 (40%) of 179 patients in the combination group, 15 (17%) of 90 in the atezolizumab group, and 18 (23%) of 80 in the regorafenib group. Two treatment-related deaths occurred in the combination group (sepsis) and one in the regorafenib group (intestinal perforation).Interpretation IMblaze370 did not meet its primary endpoint of improved overall survival with atezolizumab plus cobimetinib or atezolizumab versus regorafenib. The safety of atezolizumab plus cobimetinib was consistent with those of the individual drugs. These results underscore the challenge of expanding the benefit of immunotherapy to patients whose tumours have lower baseline levels of immune inflammation, such as those with microsatellite-stable metastatic colorectal cancer.Funding F Hoffmann-La Roche Ltd/Genentech Inc.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30027-0

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 595

Metadata

Authors
Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., Sobrero, A., Yan, Y., Chang, I., Uyei, A., Roberts, L., Ciardiello, F., Ahn, J., Asselah, J., Badarinath, S., Baijal, S., Begbie, S., Berry, S., Canon, J., Carbone, R., Cervantes, A., Cha, Y., Chang, K., Chaudhry, A., Chmielowska, E., Cho, S., Chu, D., Couture, F., Cultrera, J., Cunningham, D., Van Cutsem, E., Cuyle, P., Davies, J., Dowden, S., Dvorkin, M., Ganju, V, Garcia, R., Kerr, R., Kim, T., King, K., Kortmansky, J., Kozloff, M., Lam, K., Lee, J., Lee, A., Lesperance, B., Luppi, G., Ma, B., Maiello, E., Mandanas, R., Marshall, J., Marx, G., Mullamitha, S., Nechaeva, M., Park, J., Pavlakis, N., Ponce, C., Potemski, P., Raouf, S., Reeves, J., Segal, N., Siena, S., Smolin, A., Streb, J., Strickland, A., Szutowicz-Zielinska, E., Tabernero, J., Tan, B., Valera, J., Van den Eynde, M., Vergauwe, P., Vickers, M., Womack, M., Wroblewska, M., & Young, R.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Asan Medical Center (KR)
  • Sarah Cannon (US)
  • Universitat Autònoma de Barcelona (ES)
  • Austin Hospital (AU)
  • University of Pisa (IT)
  • City Of Hope National Medical Center (US)
  • Ospedale Policlinico San Martino (IT)
  • Genentech (US)
  • University of Campania "Luigi Vanvitelli" (IT)
  • University of Chicago (US)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Corresponding author
Ciardiello, Fortunato
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-06
Volume
20
Issue
6
Pages
849-861
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2938645074
Cited by
577
References
30
Citations by year
2026: 56 · 2025: 58 · 2024: 94 · 2023: 96 · 2022: 84 · 2021: 95 · 2020: 68 · 2019: 25
FWCI
28.38
Type
journal article
Language
en
Update notices
erratum (2019-06-01)
Open access
Licence
  • other-oa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • Digital Access to Libraries (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Funders
  • Amgen
  • AbbVie
  • Merck
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Meso Scale Diagnostics
  • Roche
  • AstraZeneca
  • Horizon Pharma
  • EMD Serono
  • MedImmune
  • Celgene
  • Genentech
  • Servier
  • Bayer
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
atezolizumab, cobimetinib, regorafenib, metastatic colorectal cancer, third-line therapy, immune checkpoint inhibitors, combination immunotherapy, overall survival, RAS status, treatment safety, adverse events
MeSH terms
Aged, Antineoplastic Combined Chemotherapy Protocols, Azetidines, Female, Follow-Up Studies, Humans, Liver Neoplasms, Male, Middle Aged, Phenylurea Compounds, Piperidines, Prognosis, Pyridines, Colorectal Neoplasms, Survival Rate, Salvage Therapy, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30027-0
The paper
Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., Sobrero, A., Yan, Y., Chang, I., Uyei, A., Roberts, L., Ciardiello, F., Ahn, J., Asselah, J., Badarinath, S., . . . Young, R. (2019). Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30027-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.